We demonstrate TOSICA’s advantages by applying it to scRNA-seq data of tumor-infiltrating immune cells, and CD14+ monocytes in COVID-19 to reveal rare cell types, heterogeneity and dynamic trajectories associated with disease progression and severity. The gene discussed is CD14; the disease is COVID-19.